DCC (Netrin receptor DCC) variants and mutations
DCC (also known as Netrin receptor DCC) is a human protein-coding gene encoding a netrin receptor protein. It guides developing axons in response to netrin signals and helps establish long-range neural connections across the midline. Heterozygous pathogenic variants can cause congenital mirror movements, while biallelic or severe variants can produce complex neurodevelopmental syndromes. This analysis covers 2,230 DCC variants and mutations. Of these, 92% have computational variant effect predictions. Disease context includes mirror movements 1, horizontal gaze palsy with progressive scoliosis, and mirror movements 1 and/or agenesis of the corpus callosum. Example DCC variants include M1T, E2A, and E2D.
Variant analysis overview
- Gene: DCC
- Protein: Netrin receptor DCC
- UniProt accession: P43146
- Organism: Homo sapiens
- Variants analyzed: 2230
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 2,037 unspecified-consequence records; 107 missense variants; 73 synonymous variants; 5 stop-gained variants; 4 frameshift variants; 2 splice-region variants; 1 in-frame deletions; 1 stop retained variant
- Prediction scores: 2,045 variants have prediction scores (92% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: mirror movements 1, horizontal gaze palsy with progressive scoliosis, mirror movements 1 and/or agenesis of the corpus callosum, Agenesis of corpus callosum, hereditary disease, autism spectrum disorder, smoking initiation, attention deficit-hyperactivity disorder, intelligence, colorectal cancer, Fuchs' endothelial dystrophy, familial congenital mirror movements.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 10 domains; 9 post-translational modification sites.
- Structural context: 1,499 variants have structural context.
- PTM context: 14 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable DCC variants
Examples include M1T, E2A, E2D, E2K, E2Q, N3K, N3S, N3H. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1T (p.Met1Thr), rs2144215711, ClinGen CA402512081, ClinVar RCV001391260, MutPred 0.57, Likely pathogenic, Partial agenesis of the corpus callosum
- E2A (p.Glu2Ala), ExAC rs768588905, gnomAD rs768588905, REVEL 0.23, MetaLR 0.15
- E2D (p.Glu2Asp), NCI-TCGA TCGA novel, MetaLR 0.16, MetaSVM -0.73, Variant assessed as somatic; moderate impact.
- E2K (p.Glu2Lys), ExAC rs779492300, TOPMed rs779492300, gnomAD rs779492300, REVEL 0.31, MetaLR 0.16
- E2Q (p.Glu2Gln), ExAC rs779492300, TOPMed rs779492300, gnomAD rs779492300, REVEL 0.30, MetaLR 0.16
- N3K (p.Asn3Lys), Ensembl rs1005837384, MetaLR 0.07, MetaSVM -1.00
- N3S (p.Asn3Ser), rs117282798, ClinGen CA8966437, ClinVar RCV003979819, 1000Genomes rs117282798, REVEL 0.06, MetaLR 0.05, Likely benign, DCC-related disorder
- N3H (p.Asn3His), gnomAD 18-52340794-A-C, REVEL 0.12, MetaLR 0.10
- N3N (p.Asn3Asn), gnomAD 18-52340796-T-C, CADD 13.20
- S4I (p.Ser4Ile), gnomAD 18-52340798-G-T, REVEL 0.32, MetaLR 0.16
- S4S (p.Ser4Ser), rs567317003, gnomAD 18-52752034-C-T, CADD 10.10
- S4T (p.Ser4Thr), rs536238178, gnomAD 18-52752041-T-A, CADD 15.70
- S4F (p.Ser4Phe), rs886274537, gnomAD 18-52752042-C-T, CADD 6.49
- L5F (p.Leu5Phe), TOPMed rs1273414468, gnomAD rs1273414468, REVEL 0.18, MetaLR 0.16
- L5V (p.Leu5Val), NCI-TCGA Cosmic COSV7144, MetaLR 0.15, MetaSVM -0.81, Variant assessed as somatic; moderate impact.
- L5R (p.Leu5Arg), gnomAD 18-52340801-T-G, REVEL 0.21, MetaLR 0.14
- L5L (p.Leu5Leu), rs1220620096, gnomAD 18-52340802-T-C, CADD 13.10
- L5P (p.Leu5Pro), rs2037002613, gnomAD 18-52752036-T-C, CADD 15.10
- R6G (p.Arg6Gly), Ensembl rs2144215790
- R6K (p.Arg6Lys), TOPMed rs1038209589
- R6I (p.Arg6Ile), gnomAD 18-52340804-G-T, REVEL 0.10, MetaLR 0.08
- C7F (p.Cys7Phe), gnomAD rs866002143, REVEL 0.13, MetaLR 0.06
- C7R (p.Cys7Arg), 1000Genomes rs547090648, ExAC rs547090648, TOPMed rs547090648, gnomAD rs547090648, REVEL 0.13, MetaLR 0.07
- C7Y (p.Cys7Tyr), gnomAD rs866002143, REVEL 0.12, MetaLR 0.07
- C7* (p.Cys7Ter), gnomAD 18-52340808-T-A, CADD 37.00
- C7S (p.Cys7Ser), gnomAD 18-52752039-G-C, CADD 2.33
- V8V (p.Val8Val), gnomAD 18-52340811-T-G, CADD 10.70
- V8F (p.Val8Phe), rs761298636, gnomAD 18-52752046-TG-T, CADD 0.89
- V8L (p.Val8Leu), rs767923423, gnomAD 18-52752047-G-C, CADD 1.26
- W9C (p.Trp9Cys), NCI-TCGA TCGA novel, TOPMed rs1983595457, REVEL 0.10, MetaLR 0.08, Variant assessed as somatic; moderate impact.
- V10A (p.Val10Ala), 1000Genomes rs192846998, ExAC rs192846998, gnomAD rs192846998, REVEL 0.11, MetaLR 0.06
- V10G (p.Val10Gly), 1000Genomes rs192846998, ExAC rs192846998, gnomAD rs192846998, REVEL 0.18, MetaLR 0.08
- V10I (p.Val10Ile), TOPMed rs1282133083, gnomAD rs1282133083, REVEL 0.08, MetaLR 0.07
- V10V (p.Val10Val), gnomAD 18-52340817-A-G, CADD 12.20
- P11H (p.Pro11His), TOPMed rs1297820968, gnomAD rs1297820968, REVEL 0.19, MetaLR 0.16
- P11L (p.Pro11Leu), gnomAD 18-52340819-C-T, REVEL 0.17, MetaLR 0.16
- P11T (p.Pro11Thr), gnomAD 18-52752050-C-A, CADD 0.41
- P11A (p.Pro11Ala), gnomAD 18-52752050-C-G, CADD 0.44
- K12R (p.Lys12Arg), gnomAD 18-52340822-A-G, REVEL 0.08, MetaLR 0.05
- K12K (p.Lys12Lys), rs776881751, gnomAD 18-52340823-G-A, CADD 12.50
- L13V (p.Leu13Val), ESP rs373864086, ExAC rs373864086, TOPMed rs373864086, gnomAD rs373864086, REVEL 0.18, MetaLR 0.14
- L13L (p.Leu13Leu), gnomAD 18-52340824-C-T, CADD 12.70
- L13P (p.Leu13Pro), gnomAD 18-52340825-T-C, REVEL 0.29, MetaLR 0.18
- A14S (p.Ala14Ser), TOPMed rs1461748482, REVEL 0.10, MetaLR 0.07
- A14A (p.Ala14Ala), gnomAD 18-52340829-T-C, CADD 15.20
- F15L (p.Phe15Leu), 1000Genomes rs2144215891, REVEL 0.20, MetaLR 0.10
- V16I (p.Val16Ile), TOPMed rs1450606224, gnomAD rs1450606224, REVEL 0.07, MetaLR 0.07
- V16V (p.Val16Val), gnomAD 18-52340835-A-G, CADD 13.50
- L17F (p.Leu17Phe), ExAC rs765345419, TOPMed rs765345419, gnomAD rs765345419, REVEL 0.16, MetaLR 0.08
- L17I (p.Leu17Ile), ExAC rs765345419, TOPMed rs765345419, gnomAD rs765345419
- L17R (p.Leu17Arg), NCI-TCGA TCGA novel, MetaLR 0.06, MetaSVM -1.04, Variant assessed as somatic; moderate impact.
- L17V (p.Leu17Val), rs765345419, ClinGen CA402512179, ClinVar RCV002896794, REVEL 0.12, MetaLR 0.08, Uncertain significance, Inborn genetic diseases
- L17L (p.Leu17Leu), gnomAD 18-52340838-C-G, CADD 11.30
- F18F (p.Phe18Phe), gnomAD 18-52340841-C-T, CADD 13.60
- G19A (p.Gly19Ala), gnomAD rs1983597057, REVEL 0.11, MetaLR 0.08
- G19R (p.Gly19Arg), gnomAD rs1355339820, REVEL 0.22, MetaLR 0.05
- G19G (p.Gly19Gly), rs1234404416, gnomAD 18-52340844-A-G, CADD 11.50
- A20T (p.Ala20Thr), gnomAD 18-52340845-G-A, REVEL 0.06, MetaLR 0.05
- A20V (p.Ala20Val), gnomAD 18-52340846-C-T, REVEL 0.07, MetaLR 0.06
- S21C (p.Ser21Cys), Ensembl rs769720354
- S21F (p.Ser21Phe), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L22F (p.Leu22Phe), NCI-TCGA Cosmic COSV1014, Variant assessed as somatic; moderate impact.
- L22L (p.Leu22Leu), rs752784027, gnomAD 18-52340851-T-C, CADD 12.00
- F23I (p.Phe23Ile), 1000Genomes rs9951523, ESP rs9951523, ExAC rs9951523, TOPMed rs9951523, REVEL 0.11, MetaLR 0.07, Benign
- F23L (p.Phe23Leu), rs9951523, ClinGen CA8966444, ClinVar RCV001661359, ClinVar RCV001661360, REVEL 0.10, MetaLR 0.00, Benign, Gaze palsy, familial horizontal, with progressive scoliosis, 2; not provided; Mi
- F23V (p.Phe23Val), 1000Genomes rs9951523, ESP rs9951523, ExAC rs9951523, TOPMed rs9951523, MetaLR 0.07, MetaSVM -1.10, Benign
- S24C (p.Ser24Cys), NCI-TCGA Cosmic COSV7142, Variant assessed as somatic; moderate impact.
- S24G (p.Ser24Gly), NCI-TCGA Cosmic COSV7142, MetaLR 0.07, MetaSVM -1.10, Variant assessed as somatic; moderate impact.
- S24R (p.Ser24Arg), NCI-TCGA Cosmic COSV1014, Ensembl rs1983598378, REVEL 0.13, MetaLR 0.07, Variant assessed as somatic; moderate impact.
- S24S (p.Ser24Ser), gnomAD 18-52340859-C-T, CADD 13.10
- A25E (p.Ala25Glu), 1000Genomes rs548959522, ExAC rs548959522, TOPMed rs548959522, gnomAD rs548959522, REVEL 0.14, MetaLR 0.06
- A25T (p.Ala25Thr), rs764708082, NCI-TCGA Cosmic COSV7143, ExAC rs764708082, gnomAD rs764708082, REVEL 0.09, MetaLR 0.06, Variant assessed as somatic; moderate impact.
- A25V (p.Ala25Val), rs548959522, NCI-TCGA Cosmic COSV7143, 1000Genomes rs548959522, ExAC rs548959522, REVEL 0.10, MetaLR 0.06, Variant assessed as somatic; moderate impact.
- A25A (p.Ala25Ala), rs1023954603, gnomAD 18-52340862-G-C, CADD 10.80
- H26L (p.His26Leu), 1000Genomes rs568806828, ExAC rs568806828, TOPMed rs568806828, gnomAD rs568806828, REVEL 0.21, MetaLR 0.08
- H26R (p.His26Arg), 1000Genomes rs568806828, ExAC rs568806828, TOPMed rs568806828, gnomAD rs568806828, REVEL 0.11, MetaLR 0.08
- H26Q (p.His26Gln), gnomAD 18-52340865-T-G, REVEL 0.10, MetaLR 0.10
- L27F (p.Leu27Phe), rs1208033056, NCI-TCGA Cosmic COSV7142, gnomAD rs1208033056, REVEL 0.10, MetaLR 0.10, Variant assessed as somatic; moderate impact.
- L27R (p.Leu27Arg), NCI-TCGA Cosmic COSV7144, MetaLR 0.09, MetaSVM -1.05, Variant assessed as somatic; moderate impact.
- L27P (p.Leu27Pro), gnomAD 18-52340867-T-C, REVEL 0.26, MetaLR 0.11
- Q28R (p.Gln28Arg), gnomAD rs1256227910, REVEL 0.12, MetaLR 0.05
- Q28H (p.Gln28His), gnomAD 18-52340871-A-T, REVEL 0.11, MetaLR 0.08
- V29G (p.Val29Gly), gnomAD 18-52340873-T-G, REVEL 0.23, MetaLR 0.15
- V29V (p.Val29Val), rs906893281, gnomAD 18-52340874-A-G, CADD 12.90
- T30T (p.Thr30Thr), gnomAD 18-52340877-C-T, CADD 14.80
- G31S (p.Gly31Ser), ExAC rs781446021, gnomAD rs781446021, REVEL 0.15, MetaLR 0.12
- G31P (p.Gly31Pro), gnomAD 18-52340875-A-ACC, CADD 27.40
- I34F (p.Ile34Phe), cosmic curated COSV10050, gnomAD rs1387130494, REVEL 0.17, CADD 22.40
- I34T (p.Ile34Thr), ExAC rs750760650, gnomAD rs750760650, REVEL 0.10, CADD 22.40
- A36D (p.Ala36Asp), ExAC rs755736951, TOPMed rs755736951, gnomAD rs755736951, REVEL 0.10, CADD 19.10
- A36T (p.Ala36Thr), gnomAD rs1175611526, REVEL 0.10, CADD 12.10
- A36V (p.Ala36Val), ExAC rs755736951, TOPMed rs755736951, gnomAD rs755736951, REVEL 0.08, CADD 18.60
- T38I (p.Thr38Ile), TOPMed rs1040684774, gnomAD rs1040684774, SIFT 0.15
- T38K (p.Thr38Lys), cosmic curated COSV10049, TOPMed rs1040684774, gnomAD rs1040684774, REVEL 0.17, CADD 23.30
- T38P (p.Thr38Pro), TOPMed rs2037003344, REVEL 0.22, CADD 25.10
- T38A (p.Thr38Ala), gnomAD 18-52752074-A-G, REVEL 0.11, CADD 21.70
- A39T (p.Ala39Thr), ExAC rs779596593, gnomAD rs779596593, REVEL 0.09, CADD 16.30
- A39V (p.Ala39Val), gnomAD rs990772793, REVEL 0.07, CADD 22.20
- L40P (p.Leu40Pro), NCI-TCGA Cosmic COSV1005, cosmic curated COSV10050, REVEL 0.25, CADD 24.70, Variant assessed as somatic; moderate impact.
- L40L (p.Leu40Leu), gnomAD 18-52752080-C-T, CADD 11.10
- R41C (p.Arg41Cys), rs962808767, NCI-TCGA Cosmic COSV5908, cosmic curated COSV59089, TOPMed rs962808767, REVEL 0.35, CADD 24.40, Variant assessed as somatic; moderate impact.
- R41G (p.Arg41Gly), TOPMed rs962808767, gnomAD rs962808767, REVEL 0.19, CADD 21.60
- R41H (p.Arg41His), rs202005334, NCI-TCGA Cosmic COSV5911, cosmic curated COSV59117, NCI-TCGA Cosmic COSV5912, REVEL 0.10, CADD 1.20, Variant assessed as somatic; moderate impact.
- R41L (p.Arg41Leu), cosmic curated COSV59123, ExAC rs202005334, TOPMed rs202005334, gnomAD rs202005334, REVEL 0.24, CADD 3.57
- R41R (p.Arg41Arg), gnomAD 18-52752085-C-T, CADD 12.80
- F42I (p.Phe42Ile), ExAC rs778444286, gnomAD rs778444286, SIFT 0.00
- F42F (p.Phe42Phe), gnomAD 18-52752088-C-T, CADD 12.90
- L43V (p.Leu43Val), gnomAD 18-52752089-C-G, REVEL 0.10, CADD 16.40
- L43L (p.Leu43Leu), rs200975371, gnomAD 18-52752091-C-T, CADD 13.20
- S44* (p.Ser44Ter), NCI-TCGA Cosmic COSV1004, cosmic curated COSV10049, Variant assessed as somatic; high impact.
- E45A (p.Glu45Ala), NCI-TCGA Cosmic COSV1005, cosmic curated COSV10050, REVEL 0.42, CADD 28.50, Variant assessed as somatic; moderate impact.
- E45K (p.Glu45Lys), ExAC rs758335110, gnomAD rs758335110, SIFT 0.00
- P46S (p.Pro46Ser), NCI-TCGA Cosmic COSV5909, cosmic curated COSV59096, Variant assessed as somatic; moderate impact.
- P46T (p.Pro46Thr), NCI-TCGA Cosmic COSV5909, SIFT 0.01, Variant assessed as somatic; moderate impact.
- P46A (p.Pro46Ala), gnomAD 18-52752098-C-G, REVEL 0.49, CADD 25.00
- S47Y (p.Ser47Tyr), NCI-TCGA Cosmic COSV5910, cosmic curated COSV59100, Variant assessed as somatic; moderate impact.
- D48H (p.Asp48His), NCI-TCGA Cosmic COSV5911, cosmic curated COSV59119, SIFT 0.00, Variant assessed as somatic; moderate impact.
- D48D (p.Asp48Asp), gnomAD 18-52752106-T-C, CADD 12.60
- A49S (p.Ala49Ser), NCI-TCGA TCGA novel, SIFT 1.00, Variant assessed as somatic; moderate impact.
- A49A (p.Ala49Ala), rs777555256, gnomAD 18-52752109-C-T, CADD 2.13
- V50I (p.Val50Ile), cosmic curated COSV59142, 1000Genomes rs148156622, ExAC rs148156622, TOPMed rs148156622, REVEL 0.03, CADD 5.66
- T51A (p.Thr51Ala), cosmic curated COSV10589, 1000Genomes rs190581937, ExAC rs190581937, TOPMed rs190581937, REVEL 0.17, CADD 15.20
- T51I (p.Thr51Ile), NCI-TCGA Cosmic COSV5912, cosmic curated COSV59125, SIFT 0.02, Variant assessed as somatic; moderate impact.
- T51P (p.Thr51Pro), 1000Genomes rs190581937, ExAC rs190581937, TOPMed rs190581937, gnomAD rs190581937, REVEL 0.19, CADD 24.30
- T51T (p.Thr51Thr), gnomAD 18-52752115-A-G, CADD 0.50
- M52I (p.Met52Ile), gnomAD rs1229149749, REVEL 0.13, CADD 18.40
- M52V (p.Met52Val), ExAC rs775883937, TOPMed rs775883937, gnomAD rs775883937, REVEL 0.12, CADD 14.10
- R53P (p.Arg53Pro), ExAC rs768831554, TOPMed rs768831554, gnomAD rs768831554, REVEL 0.24, CADD 27.40
- R53Q (p.Arg53Gln), rs768831554, NCI-TCGA Cosmic COSV5909, cosmic curated COSV59091, ExAC rs768831554, REVEL 0.12, CADD 23.10, Variant assessed as somatic; moderate impact.
- R53W (p.Arg53Trp), rs749558240, NCI-TCGA Cosmic COSV5909, cosmic curated COSV59091, NCI-TCGA Cosmic COSV5910, REVEL 0.28, CADD 25.80, Variant assessed as somatic; moderate impact.
- R53R (p.Arg53Arg), rs749558240, gnomAD 18-52752119-C-A, CADD 9.68
- G54E (p.Gly54Glu), cosmic curated COSV59098, Ensembl rs2037004481, REVEL 0.56, CADD 25.90
- G54R (p.Gly54Arg), cosmic curated COSV10517, gnomAD rs1355008328, REVEL 0.50, CADD 26.80
- G54A (p.Gly54Ala), gnomAD 18-52752123-G-C, REVEL 0.46, CADD 25.20
- G55E (p.Gly55Glu), rs145690431, NCI-TCGA Cosmic COSV5908, cosmic curated COSV59083, gnomAD rs145690431, REVEL 0.20, CADD 22.40, Variant assessed as somatic; moderate impact.
- G55R (p.Gly55Arg), rs2145132802, ClinGen CA402512905, ClinVar RCV001768632, Ensembl rs2145132802, MutPred 0.77, Uncertain significance, not provided
- N56I (p.Asn56Ile), Ensembl rs2037004571, SIFT 0.27
- N56H (p.Asn56His), gnomAD 18-52752128-A-C, REVEL 0.08, CADD 19.80
- N56N (p.Asn56Asn), rs1405842057, gnomAD 18-52752130-T-C, CADD 0.24
- V57F (p.Val57Phe), cosmic curated COSV59106, gnomAD rs1418624209, REVEL 0.23, CADD 23.10
- V57D (p.Val57Asp), gnomAD 18-52752132-T-A, REVEL 0.41, CADD 24.30
- V57V (p.Val57Val), gnomAD 18-52752133-C-G, CADD 3.28
- L58I (p.Leu58Ile), NCI-TCGA TCGA novel, REVEL 0.06, CADD 10.70, Variant assessed as somatic; moderate impact.
- L58F (p.Leu58Phe), gnomAD 18-52752134-C-T, REVEL 0.07, CADD 14.50
- L59F (p.Leu59Phe), NCI-TCGA Cosmic COSV5911, cosmic curated COSV59117, REVEL 0.23, CADD 23.40, Variant assessed as somatic; moderate impact.
- L59I (p.Leu59Ile), ExAC rs762319358, TOPMed rs762319358, gnomAD rs762319358, REVEL 0.18, CADD 23.20
- L59P (p.Leu59Pro), NCI-TCGA Cosmic COSV5914, cosmic curated COSV59143, REVEL 0.65, CADD 25.20, Variant assessed as somatic; moderate impact.
- L59H (p.Leu59His), gnomAD 18-52752138-T-A, REVEL 0.59, CADD 24.70
- L59L (p.Leu59Leu), gnomAD 18-52752139-C-G, CADD 0.36
- D60Y (p.Asp60Tyr), cosmic curated COSV59102, TOPMed rs1347472471, gnomAD rs1347472471, REVEL 0.21, CADD 22.90
- S62S (p.Ser62Ser), rs767925738, gnomAD 18-52752148-C-A, CADD 0.26
- A63T (p.Ala63Thr), rs558026226, NCI-TCGA Cosmic COSV1005, cosmic curated COSV10050, 1000Genomes rs558026226, REVEL 0.24, CADD 24.00, Variant assessed as somatic; moderate impact.
- A63V (p.Ala63Val), ExAC rs760978364, TOPMed rs760978364, gnomAD rs760978364, REVEL 0.19, CADD 18.10
- A63A (p.Ala63Ala), rs1442612330, gnomAD 18-52752151-G-A, CADD 0.91
- E64A (p.Glu64Ala), gnomAD rs1277460641, REVEL 0.08, CADD 21.40
- E64K (p.Glu64Lys), cosmic curated COSV10517, TOPMed rs1482775048, SIFT 0.06
- E64E (p.Glu64Glu), gnomAD 18-52752154-G-A, CADD 5.69
- S65S (p.Ser65Ser), rs766772715, gnomAD 18-52752157-C-A, CADD 0.55
- D66E (p.Asp66Glu), NCI-TCGA Cosmic COSV5910, cosmic curated COSV59107, NCI-TCGA Cosmic COSV5913, SIFT 0.22, Variant assessed as somatic; moderate impact.
- D66N (p.Asp66Asn), cosmic curated COSV59115, 1000Genomes rs144331156, ESP rs144331156, ExAC rs144331156, REVEL 0.11, CADD 22.80
- R67Q (p.Arg67Gln), cosmic curated COSV10049, ESP rs146575994, ExAC rs146575994, gnomAD rs146575994, REVEL 0.06, CADD 17.70
- R67R (p.Arg67Arg), gnomAD 18-52752161-C-A, CADD 10.00
- R67P (p.Arg67Pro), gnomAD 18-52752162-G-C, REVEL 0.19, CADD 17.80
- G68E (p.Gly68Glu), rs752208238, NCI-TCGA Cosmic COSV1004, cosmic curated COSV10049, ExAC rs752208238, REVEL 0.13, MetaLR 0.01, Variant assessed as somatic; moderate impact.
- V69D (p.Val69Asp), TOPMed rs1326511847, REVEL 0.09, MetaLR 0.01
- V69I (p.Val69Ile), gnomAD rs1273613913, REVEL 0.07, MetaLR 0.01
- V69V (p.Val69Val), gnomAD 18-52752169-T-C, CADD 4.81
- P70S (p.Pro70Ser), NCI-TCGA Cosmic COSV5910, cosmic curated COSV59101, MetaLR 0.13, MetaSVM -0.89, Variant assessed as somatic; moderate impact.
- P70P (p.Pro70Pro), rs1038717902, gnomAD 18-52752172-A-C, CADD 1.77
- V71M (p.Val71Met), TOPMed rs893585925, gnomAD rs893585925, REVEL 0.05, MetaLR 0.03
- K73Q (p.Lys73Gln), NCI-TCGA Cosmic COSV5911, cosmic curated COSV59113, MetaLR 0.02, MetaSVM -0.94, Variant assessed as somatic; moderate impact.
- K73R (p.Lys73Arg), rs141272344, cosmic curated COSV10963, ESP rs141272344, ExAC rs141272344, REVEL 0.06, MetaLR 0.02, Variant assessed as somatic; moderate impact.
- K73K (p.Lys73Lys), rs199598105, gnomAD 18-52752181-G-A, CADD 10.30
- W74* (p.Trp74Ter), NCI-TCGA Cosmic COSV1005, cosmic curated COSV10050, Variant assessed as somatic; high impact.
- W74L (p.Trp74Leu), NCI-TCGA Cosmic COSV1004, cosmic curated COSV10049, MetaLR 0.55, MetaSVM 0.49, Variant assessed as somatic; moderate impact.
- K75N (p.Lys75Asn), rs1469635869, ClinGen CA402513036, ClinVar RCV002892187, TOPMed rs1469635869, REVEL 0.18, MetaLR 0.10, Uncertain significance, Inborn genetic diseases
- K75R (p.Lys75Arg), gnomAD 18-52752186-A-G, REVEL 0.03, MetaLR 0.02
- K76N (p.Lys76Asn), Ensembl rs1568081800, REVEL 0.45, MetaLR 0.18
- K76E (p.Lys76Glu), gnomAD 18-52752188-A-G, REVEL 0.66, MetaLR 0.20
- D77H (p.Asp77His), gnomAD 18-52752191-G-C, REVEL 0.69, MetaLR 0.06
Public DCC analysis runs
- DCC analysis run — DCC (2,230 variants) — completed 2026-08-19